Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Recurrence × Anastrozole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 53 Neoplasms 5 Neoplasm Metastasis 4 Advanced Breast Cancer 4 Skin Diseases 1 Recurrence 1 Quality of Life 1 Neoplasms by Site 1 Low Grade Serous Ovarian Cancer 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Carcinoma, Ductal, Breast 1 Camurati-Engelmann Syndrome 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Carcinoma In Situ 1 Breast Cancer Metastatic 1 Breast Cancer Female 1 Bone Density 1 Advanced Metastatic Breast Cancer 1

Interventions

Dexamethasone 21 Rituximab 13 Paclitaxel 10 Gemcitabine 10 Cisplatin 10 pomalidomide 9 Lenalidomide 9 Carboplatin 8 Bortezomib 8 Cyclophosphamide 7 Drug Therapy 5 Cytarabine 5 selinexor 4 daratumumab 4 carfilzomib 4 Temozolomide 4 Doxorubicin 4 Docetaxel 4 Bevacizumab 4 Aspirin 4 tisagenlecleucel 3 ibrutinib 3 Vincristine 3 Prednisone 3 Cetuximab 3 Calcium Dobesilate 3 galiximab 2 eculizumab 2 durvalumab 2 blinatumomab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡